Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26
Caris Life Sciences (NASDAQ: CAI) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. A conference call and live webcast will be held at 3:30 p.m. CT (4:30 p.m. ET) to discuss the results.
Investors can join the live webcast at the provided media-server link and access a replay shortly after the call on the company's Investor Relations website.
Details
News Market Reaction – CAI
On Feb 9, the day this news came out, CAI closed 1.41% above the previous close.
Data tracked by StockTitan Argus for the Feb 9 session.
Key Figures
- Earnings report date
- February 26, 2026
- Q4 and full year 2025 financial results release
- Earnings call time
- 3:30 p.m. CT
- Scheduled conference call to discuss results
- Earnings call time
- 4:30 p.m. ET
- Corresponding Eastern Time for the conference call
Historical Context
-
Real-world multiomic study on T-DXd responses and resistance in breast cancer.
-
Preliminary Q4 and 2025 results showing strong revenue growth and case volume.
-
Everlywell partnership to distribute forthcoming Caris Detect MCED blood assay.
-
Participation and webcast at the 44th Annual J.P. Morgan Healthcare Conference.
-
Providence Swedish Cancer Institute joined the Caris Precision Oncology Alliance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.
Conference Call Details:
Date: Thursday, February 26, 2026
Time: 3:30 p.m. CT (4:30 p.m. ET)
Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4
A replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
Investor Relations:
IR@CarisLS.com
917.689.3511
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-302681818.html
SOURCE Caris Life Sciences
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.